About Us

GlycoMimetics is a publicly traded, clinical-stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs.

Our Management Team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.

Since the company’s inception in 2003, GlycoMimetics has developed a robust, diversified product pipeline.

The company’s mission is to continue to advance its pipeline, providing hope for patients with sickle cell, cancer, and other serious diseases.

Nasdaq

The GlycoMimetics, Inc. [NASDAQ: GLYC] team visited the NASDAQ MarketSite in Times Square (New York) on April 11, 2014.
The GLYC initial public offering on January 10, 2014 was the first of the year on all U.S. exchanges.